Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epidemiological studies suggest that, even in communities with high infection rates, herd immunity through natural infection may not have been achieved, and these studies raise the possibility that a combination of waning immunity and viral antigenic variation may allow for continued circulation of the virus11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manaus experienced a strong wave of SARS-CoV-2 infection in April and May of 2020, which might have been expected to provide some level of protection or herd immunity in the exposed population. However, despite a low level of transmission from June to December 2020, a resurgence of infection was observed in early 2021 (refs11,57).”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with the seroepidemiological evidence for ongoing spread of infection in a highly exposed population in Manaus, which suggests that there may be susceptibility to reinfection after 6–8 months11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Several studies have estimated cumulative infections in select countries at specific points in time.6, 7, 8, 9”
From Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Self-citationFerguson, N. M., Laydon, D. J., Nedjati-Gilani, G. L., Imai, N., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z. M., Cuomo-Dannenburg, G., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77482 · Cited by 3,281
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Empirical Likelihood and General Estimating Equations
Qin, J., & Lawless, J. (1994) · The Annals of Statistics · doi:10.1214/aos/1176325370 · Cited by 1,715
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TEST
ROGAN, W. J., & GLADEN, B. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112510 · Cited by 1,001
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Research works printed but not linked: 1
- 10.1186/1742-7622-9-9 · DOI
Cited by
Items 201–300 of 486
The potential impact of COVID-19 on male reproductive health
Nguyen, T. T., Hulme, J., Tran, H. D., Vo, T. K., & Giau, V. V. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01764-z · Cited by 17
COVID-19 Modeling Outcome versus Reality in Sweden
Carlsson, M., & Söderberg‐Nauclér, C. (2022) · Viruses · doi:10.3390/v14081840 · Cited by 13
COVID-19 Mortality in Brazil, 2020-21: Consequences of the pandemic inadequate managementPreprint
Szwarcwald, C. L., Boccolini, C. S., de Almeida, W. D. S., Filho, A. M. S., & Malta, D. C. (2022) · Research Square · doi:10.21203/rs.3.rs-1678072/v1 · Cited by 14
Anand, S., Montez‐Rath, M. E., Han, J., Cadden, L., Hunsader, P., KERSCHMANN, R. L., Beyer, P., Boyd, S. D., García, P., Dittrich, M. O., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.16572 · Cited by 10
Implications derived from S-protein variants of SARS-CoV-2 from six continents
Hassan, S. S., Lundstrom, K. H., Barh, D., Silva, R. J. S., Andrade, B. S., Azevedo, V., Choudhury, P. P., Palù, G., Uhal, B. D., Kandimalla, R. J. L., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.09.080 · Cited by 13
“…status in South America may be summarized by the example of Manaus (the capital of Amazonas state in northern Brazil) where from June 2020 to October 2020 the SARS-CoV-2 prevalence among the population increased from ~60% to ~70%, a condition which may mirror acquisition of herd immunity [46].”
Sulaeman, H., Grebe, E., Dave, H., McCann, L., Germanio, C. D., Sanghavi, A., Sclar, V., Bougie, D. W., Chatelain, G., Biggerstaff, B. J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03234-22 · Cited by 12
“All specimens were tested for anti-S and anti-NC antibodies on both Ortho (Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 Total Antibody Test, Vitros 3600 & Vitros 7600, Raritan, NJ) and Roche (Roche Elecsys Anti-SARS-CoV-2 antibody test, Roche cobas e 411, Basel, Switzerland) platforms.”
Self-citationXu, H., Wang, B., Zhao, T.-N., Liang, Z., Peng, T., Song, X., Wu, J., Wang, Y., & Su, X. (2021) · Cell Research · doi:10.1038/s41422-021-00554-1 · Cited by 13
Vaccines for Covid‐19: An insight on their effectiveness and adverse effects
Qamar, N., Rukh, G., & Khan, S. N. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27810 · Cited by 13
Alandijany, T. A., El-Kafrawy, S. A., Alghamdi, A., Qashqari, F. S., Faizo, A. A., Tolah, A. M., Hassan, A. M., Sohrab, S. S., Hindawi, S., Badawi, M. A., et al. (2021) · Healthcare · doi:10.3390/healthcare9010051 · Cited by 12
The COVID‐19 pandemic: key considerations for the epidemic and its control
Ørskov, S., Nielsen, B. F., Føns, S., Sneppen, K., & Simonsen, L. (2021) · Apmis · doi:10.1111/apm.13141 · Cited by 13
“first wave had apparently conferred herd immunity [84, 85].”
Serum antibody response to BNT162b2 after natural SARS‐CoV‐2 infection
Perkmann, T., Perkmann‐Nagele, N., Köller, T., Mucher, P., Radakovics, A., Wolzt, M., Wagner, O. F., Binder, C. J., & Haslacher, H. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13632 · Cited by 11
Melotti, R., Scaggiante, F., Falciani, M., Weichenberger, C. X., Foco, L., Lombardo, S., Grandi, A. D., von Laer, D., Mahlknecht, A., Pramstaller, P. P., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821001886 · Cited by 13
“[13, 14] However, the Manaus case shows that it might still result in a non-negligible underestimation of the true infection rate.[15] Several reasons suggest that our estimate should be considered as a lower bound of the real seroprevalence.”
BackgroundBarros, A. J. D., Victora, C. G., Menezes, A. M. B., Horta, B. L., Barros, F. C., Hartwig, F. P., Victora, G. D., Vidaletti, L. P., da Silveira, M. F., Mesenburg, M. A., et al. (2021) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2021055004075 · Cited by 12
Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon
Torres, M. K. D. S., Lopes, F. T., de Lima, A. C. R., Lima, C. N. C., Brito, W. R. D. S., dos Santos, B. C., de Sousa, R. S., Gomes, J. L. C., Botelho, B. J. S., Correa, A. C. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12629-z · Cited by 12
Takahashi, S., Peluso, M. J., Hakim, J. M. C., Turcios, K., Janson, O., Routledge, I., Busch, M. P., Hoh, R., Tai, V., Kelly, J. D., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad106 · Cited by 13
Self-citationRisk assessment and antibody responses to SARS-CoV-2 in healthcare workers
Bansal, A., Trieu, M.-C., Mohn, K. G.-I., Madsen, A., Olofsson, J. S., Sandnes, H. H., Sævik, M., Søyland, H., Hansen, L., Onyango, T. B., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1164326 · Cited by 13
“In our study, 24% (15/63) of infected HCWs became seronegative by 8 months, suggesting a need for COVID-19 vaccination in HCWs ∼6 months after mild-to-moderate SARS-CoV-2 infection (61).”
BackgroundEvolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm
Yépez, Y., Marcano-Ruiz, M., Bezerra, R. S., Fam, B., Ximenez, J. P., Silva, W. A., Jr., & Bortolini, M. C. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2021-0309 · Cited by 16
Carvalho, C. L. C., Nascimento, S. Q., Bertaglia, T., Faria, L. C. I., Manuli, E. R., Pereira, G. M., Cantanhêde, W., Costa, C. M., Maestu, J. F., Lanceros-Méndez, S., et al. (2025) · ACS Sensors · doi:10.1021/acssensors.4c03175 · Cited by 13
SARS-CoV-2 epidemiology, kinetics, and evolution: A narrative review
Alizon, S., & Sofonea, M. T. (2025) · Virulence · doi:10.1080/21505594.2025.2480633 · Cited by 16
“The magnitude of the first epidemic wave in the city is difficult to assess, but it could be in the order of 2/3, with dramatic consequences for the inha-bitants [98] (Figure 5b).”
Kittikraisak, W., Hunsawong, T., Punjasamanvong, S., Wongrapee, T., Suttha, P., Piyaraj, P., Leepiyasakulchai, C., Tanathitikorn, C., Yoocharoen, P., Jones, A. R., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12975 · Cited by 11
Hunger and its associated factors in the western Brazilian Amazon: a population-based study
da Mata, M. M., Neves, J. A., & de Medeiros, M. A. T. (2022) · Journal of Health Population and Nutrition · doi:10.1186/s41043-022-00319-5 · Cited by 17
“In May 2020, its capital, Manaus, reached the epidemic peak, and in October of the same year, the attack rate by antibodies detectable (76%) exceeded the estimate for the state of São Paulo in the Southeast Region (29%) [6], the Brazilian state with the third highest population density in the country [7].”
BackgroundDeciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin
Ballesteros, N., Muñoz, M., Patiño, L. H., Hernández, C., González-Casabianca, F., Carroll, I., Santos‐Vega, M., Cascante, J., Ángel, A., Feged-Rivadeneira, A., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009327 · Cited by 14
Aubry, A., Demey, B., François, C., Duverlie, G., Castelain, S., Helle, F., & Brochot, É. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091815 · Cited by 10
“Moreover, mathematical models used to extrapolate these seroprevalence data may be highly influenced by such disparities, as observed for seroprevalence studies in the city of Manaus in Brazil [10,11].”
BackgroundGaray, E., Coll, H. A. S., Rivero, R., Gastelbondo, B., Faccini‐Martínez, Á. A., Berrocal, J., Perez, A. G., Badillo, M., Martínez, C., Botero, Y., et al. (2021) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trab094 · Cited by 11
Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm
Mora, Y. B. Y., Marcano-Ruiz, M., Bezerra, R. D. S., Fam, B. S. D. O., Ximenez, J. P. B., Silva, W. A., & Bortolini, M. C. (2022) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 11
Buss, L., Junior, C. A. P., Whittaker, C., Salomon, T., Oikawa, M. K., Pereira, R. H. M., Moura, I. C. G., Delerino, L., França, R. F. D. O., Miyajima, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10091437 · Cited by 10
“This cohort has been described in detail previously [9,14,23].”
BackgroundMethodInfluentialSelf-citationINFERRED RESOLUTION THROUGH HERD IMMMUNITY OF FIRST COVID-19 WAVE IN MANAUS, BRAZILIAN AMAZONPreprint
Prowse, T. A. A., Purcell, T., Baía-da-Silva, D. C., Sampaio, V. D. S., Monteiro, W. M., Wood, J., Müeller, I., McVernon, J., Lacerda, M., & Ross, J. V. (2020) · medRxiv · doi:10.1101/2020.09.25.20201939 · Cited by 11
Soldatov, A. A., Kryuchkov, N. A., Витальевич, Г. Д., Авдеева, Ж. И., Свитич, О. А., & Soshnikov, S. S. (2025) · Vaccines · doi:10.3390/vaccines13080789 · Cited by 13
“Antibodies to early SARS-CoV-2 strains have shown significantly reduced cross-reactive neutralizing activity against the Delta and Omicron variants, leading to an increase in reinfection rates in many regions of the world [39–41].”
Kotsiou, O. S., Papagiannis, D., Fradelos, Ε. C., Perlepe, G., Miziou, A., Siachpazidou, D. S., & Gourgoulianis, K. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132765 · Cited by 10
“The same epidemic curves of the COVID-19 outbreak have also been recorded in other places worldwide [7,8].”
BackgroundCaveats on COVID-19 herd immunity threshold: the Spain case
García‐García, D., Morales, E., Fonfría, E. S., Vigo, I., & Bordehore, C. (2022) · Scientific Reports · doi:10.1038/s41598-021-04440-z · Cited by 15
“In October 2020, it was thought that Manaus had reached the HIT with 76% of infected population [30], which led to a relaxation of the control measures.”
Backgrounddo Vale, N. M. R., Latini, F. R. M., Arnoni, C. P., Parreira, R. M., Girão, M. J. B. C., Cortez, A. J. P., & Bonetti, T. C. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100016 · Cited by 10
“Additionally, two studies have discussed seroprevalence in blood donors from Rio de Janeiro, Manaus, and S~ao Paulo, Brazil.”
SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil
Chaves, D. G., Takahashi, R. H. C., Campelo, F., Malta, M. C. F. D. S., de Oliveira, I. R., Barbosa‐Stancioli, E. F., Ribeiro, M. A., & Martins, M. L. (2022) · Emerging infectious diseases · doi:10.3201/eid2804.211961 · Cited by 14
“Results obtained in other studies using the same chemiluminescence test indicated a lower sensitivity to detect SARS-CoV-2 IgG in newly infected persons (28), which might affect the extrapolation of seroprevalence data to the population when using blood donors’ samples (11,29).”
ResultIncreasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology
Perkmann, T., Köller, T., Perkmann‐Nagele, N., Ozsvár-Kozma, M., Eyre, D. W., Matthews, P. C., Bown, A., Stoesser, N. E., Breyer, M., Breyer‐Kohansal, R., et al. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208171 · Cited by 12
Monteiro, H. S., Neto, A. S. L., Kahn, R. J., de Sousa, G. D. S., Carmona, H. A., Andrade, J. S., & Castro, M. C. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.065 · Cited by 11
Self-citationDuong, S., Burtniak, J., Gretchen, A., Mai, A., Klassen, P., Wei, Y., Loeppky, C., Shaw, S. Y., Bullard, J., Caeseele, P. G. V., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-17239-6 · Cited by 10
“3) [5, 14, 15].”
MethodVonderschmitt, J., Wöhlke, S., & Schicktanz, S. (2023) · BMC Public Health · doi:10.1186/s12889-023-17249-4 · Cited by 10
Lindan, C., Desai, M., Boothroyd, D. B., Judson, T. J., Bollyky, J., Sample, H. A., Weng, Y., Cheng, Y., Dahlen, A., Hedlin, H., et al. (2021) · Annals of Epidemiology · doi:10.1016/j.annepidem.2021.11.001 · Cited by 11
Saeed, S., Uzicanin, S., Lewin, A., Lieshout‐Krikke, R. W., Faddy, H. M., Erikstrup, C., Osiowy, C., Seed, C. R., Steele, W. R., Davison, K. L., et al. (2021) · Vox Sanguinis · doi:10.1111/vox.13221 · Cited by 9
“8% but after adjusting for waning antibodies, seroprevalence rates were as high as 76% [43].”
BackgroundMethodInfluentialSelf-citationGoldenbogen, B., Adler, S. O., Bodeit, O., Wodke, J. A. H., Escalera‐Fanjul, X., Korman, A., Krantz, M., Bonn, L., Torres, R. M., Haffner, J., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-128597/v1 · Cited by 11
Duarte, G. G., Coutinho, C. M., Rolnik, D. L., Quintana, S. M., Silva, A. C. R. E., Poon, L. C., & Costa, F. D. S. (2021) · AJOG Global Reports · doi:10.1016/j.xagr.2021.100020 · Cited by 12
Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27726 · Cited by 10
Fundamental bound on epidemic overshoot in the SIR model
Nguyen, M., Freedman, A. S., Ozbay, S. A., & Levin, S. A. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2023.0322 · Cited by 14
Li, S. L., Junior, C. A. P., Zarebski, A. E., Santos, A. A. D. S., Sabino, É. C., Nascimento, V. H., Wu, C., & Messina, J. P. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076354 · Cited by 16
“States from the North and Northeast regions, such as Amazonas, Amapá and Ceará, were prioritised for vaccination in January 2021 due to high transmission rates of the P.1 (Gamma) variant, which was first detected in Manaus (the capital of Amazonas) in January 2021 (Buss et al 17 , 2021).”
BackgroundSelf-citationAndrey, D. O., Yerly, S., Meyer, B., Arm‐Vernez, I., Roux‐Lombard, P., Togni, G., Guessous, I., Spechbach, H., Stringhini, S., Agoritsas, T., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081605 · Cited by 9
Sathler, D., & Leiva, G. D. C. (2022) · Revista Brasileira de Estudos de População · doi:10.20947/s0102-3098a0205 · Cited by 13
Spira, B. (2022) · Cureus · doi:10.7759/cureus.26486 · Cited by 11
“An assessment of the COVID-19 prevalence in Manaus in October 2020 (before the emergence of the gamma variant) based on an extrapolation of seroprevalence data came out with an incredibly low IFR based on an estimated attack rate of 76% [42], a proportion at or close to the herd immunity of Manaus’ population.”
MethodSymptomatic but not Asymptomatic COVID-19 Impairs Conditioned Pain Modulation in Young Adults
Peterson, J. A., Bemben, M. G., Larson, R. D., Pereira, H. M., Crowson, H. M., & Black, C. D. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.06.010 · Cited by 9
Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
Butterfield, T. R., Bruce-Mowatt, A., Phillips, Y. Z. R., Brown, N., Francis, K., Brown, J., Walker, J. P., McKnight, N. A. L., Ehikhametalor, K., Taylor, D. K., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.059 · Cited by 9
Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?Preprint
Yu, H., Yang, J., Marziano, V., Deng, X., Guzzetta, G., Zhang, J., Trentini, F., Cai, J., Poletti, P., Zheng, W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-200069/v1 · Cited by 10
Two waves of COIVD-19 in Brazilian cities and vaccination impact
Lin, L., Chen, B., Zhao, Y., Wang, W., & He, D. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022216 · Cited by 11
Selvavinayagam, T. S., Anavarathan, S., Selvam, J. M., Sampath, P., Vijayalakshmi, V., Kumar, C. A. B., Subramaniam, S., Parthipan, K., Raju, S., Avudaiselvi, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50338-3 · Cited by 12
On the usefulness of the bioclimatic correlative models of SARS-CoV-2
Gutiérrez-Hernández, O., & García, L. V. (2021) · Environmental Research · doi:10.1016/j.envres.2021.110818 · Cited by 9
Novikova, E. A., Петрова, А. Г., Moskaleva, E. V., Vanyarkinа, A. S., & Rychkova, L. V. (2021) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2021-6.2.5 · Cited by 9
Cuykx, M., Mortelé, O., Jansens, H., Schouwers, S., Meskal, A., Hoffbauer, I., & Peeters, B. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115486 · Cited by 8
Shen, Y., Huo, D., Yu, T., & Wang, Q. (2022) · China CDC Weekly · doi:10.46234/ccdcw2022.014 · Cited by 8
Metzger, C., Leroy, T., Bochnakian, A., Jeulin, H., Gégout‐Petit, A., Legrand, K., Schvoerer, É., & Guillemin, F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0269104 · Cited by 11
Modelling the unexpected dynamics of COVID-19 in Manaus, Brazil
He, D., Artzy‐Randrup, Y., Musa, S. S., Gräf, T., Naveca, F. G., & Stone, L. (2024) · Infectious Disease Modelling · doi:10.1016/j.idm.2024.02.012 · Cited by 31
“In all cases, the method accurately reproduces the two-wave COVID-19 dynamics in Manaus without considering large reinfection rates, as in other studies (Buss et al., 2020; Faria et al., 2021a).”
BackgroundMethodResultInfluentialAbela, I. A., Pasin, C., Schwarzmüller, M., Epp, S., Sickmann, M. E., Schanz, M. M., Rusert, P., Weber, J., Schmutz, S., Audigé, A., et al. (2021) · medRxiv · doi:10.1101/2021.04.21.21255410 · Cited by 8
Lalwani, P. J., Salgado, B. B., Filho, I. V. P., da Silva, D. S. S., de Morais, T. B. D. N., Jordão, M. F., Barbosa, A. R. C., Cordeiro, I. B., Neto, J. N. D. S., de Assunção, E. N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3774177 · Cited by 12
Vaccination for COVID-19 control and considerations for Australia
MacIntyre, C. R. (2021) · Microbiology Australia · doi:10.1071/ma21009 · Cited by 7
Ribeiro, S. P., Reis, A. B., Dáttilo, W., Silva, A. C. E., Barbosa, E. A. G., Coura‐Vital, W., Goés‐Neto, A., Azevedo, V., & Fernandes, G. W. (2021) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202120210431 · Cited by 8
Correcting for Antibody Waning in Cumulative Incidence Estimation From Sequential Serosurveys
Kadelka, S., Bouman, J. A., Ashcroft, P., & Regoes, R. R. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad226 · Cited by 5
“While this cumulative incidence should have conferred herd immunity and curbed the epidemic (25– 27), Manaus was hit by a very strong second wave in January 2021 (28, 29).”
BackgroundMethodResultInfluentialPékpé, K. M., Zitouni, D., Gasso, G., Dhifli, W., & Guinhouya, B. C. (2021) · Applied Intelligence · doi:10.1007/s10489-021-02379-2 · Cited by 7
Buchan, B. W., & Yao, J. D. C. (2021) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2021.05.004 · Cited by 7
“However, the prevalence of SARSCoV-2-specific immune memory at the population level may not be sufficient to generate variants driven primarily by escape from antibodies [19].”
BackgroundEstimated prevalence of COVID-19 in Brazil with probabilistic bias correction
de Figueirêdo, E. A., Polli, D. A., & de Andrade, B. B. (2021) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00290120 · Cited by 7
Magalis, B. R., Rich, S. N., Tagliamonte, M. S., Mavian, C. N., Cash, M. N., Riva, A., Marini, S., Amador, D. M., Zhang, Y., Shapiro, J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac197 · Cited by 7
Barbosa, P. M., Júnior, F. C. D. S., Lima, G. M. C., Bertini, S., de Lima, R. R., Furuta, K. A., Mapa, C. H., Roschel, L., & de Oliveira, E. S. (2022) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2022e11959 · Cited by 6
“A previous serological study using blood samples from Manaus, the Amazonas state capital, showed that nearly 75% of the population had been infected by the SARS-CoV-2 by October 2020 (9).”
MethodPrevalence of SARS-CoV-2 antibodies after the Omicron surge, Kingston, Jamaica, 2022
Anzinger, J. J., Cameron-McDermott, S. M., Phillips, Y. Z. R., Mendoza, L., Anderson, M., Cloherty, G., Strachan-Johnson, S., Lindo, J., & Figueroa, J. P. (2022) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2022.100124 · Cited by 8
Raymundo, C. E., Oliveira, M. C., Eleutério, T. D. A., Santos, É. C. D. A., da Silva, M. G., André, S. R., Sousa, A. I., & Medronho, R. D. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-31046-4 · Cited by 15
Scale-free dynamics of COVID-19 in a Brazilian city
Policarpo, J. M. P., Ramos, A. A. G. F., Dye, C., Faria, N. R., Leal, F. E., Moraes, O. J. S., Parag, K. V., Peixoto, P. S., Buss, L., Sabino, É. C., et al. (2023) · Applied Mathematical Modelling · doi:10.1016/j.apm.2023.03.039 · Cited by 8
Self-citationSeroprevalence of SARS-CoV-2 in Brazil: A systematic review and meta-analysis
Figueiredo, G. M., Tengan, F. M., Campos, S. R. D. S. L. D. C., & Luna, E. J. D. A. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100233 · Cited by 9
“[24] At the other extreme, the Central-West region had a lower seroprevalence, even considering that this region had a lower number of surveys carried out, compared to other regions.”
BackgroundResultWendel, S., Fachini, R. M., Fontão‐Wendel, R., Mello, R., Velasquez, C. V., Machado, R. R. G., Brito, M., Amaral, M., Soares, C. P., Achkar, R., et al. (2021) · Transfusion · doi:10.1111/trf.16714 · Cited by 6
Silva, A. V. F. G., Menezes, D., Moreira, F. R. R., Torres, O. A., Fonseca, P. L. C., Moreira, R. G., Alves, H. J., Alves, V. R., Amaral, T. M. D. R., Coelho, A. N., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.799713 · Cited by 10
“, 2021) despite high seroprevalence (Buss et al., 2021), likely due to the gamma variant (Faria et al.”
BackgroundTrajectory of COVID-19 epidemic in EuropePreprint
Colombo, M., Mellor, J., Colhoun, H. M., Gomes, M. G. M., & McKeigue, P. (2020) · medRxiv · doi:10.1101/2020.09.26.20202267 · Cited by 7
Seroprevalence of Anti-SARS-CoV-2 Antibodies in Iquitos, Loreto, PeruPreprint
Álvarez-Antonio, C., Meza‐Sánchez, G., Calampa, C., Casanova, W., Carey, C., Alava, F., Rodríguez, H., & Quispe, A. M. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3759629 · Cited by 7
Oliveira, J. R., Machado, R. R. G., Arcuri, H. A., Magawa, J. Y., Daher, I. P., Urbanski, A. H., Schmitz, G. J. H., Silva, R. C. V., Durigon, E. L., Boscardin, S. B., et al. (2021) · medRxiv · doi:10.1101/2021.03.11.21253399 · Cited by 6
“of SARS-CoV2 infection in the first wave of the pandemic from March to July of 2020 (18).”
The new SARS-CoV-2 variant and reinfection in the resurgence of COVID-19 outbreaks in Manaus, BrazilPreprint
He, D., Fan, G., Wang, X., Li, Y., & Peng, Z. (2021) · medRxiv · doi:10.1101/2021.03.25.21254281 · Cited by 11
“Methods Denote the daily COVID-19 antibody sero-prevalence (those defined (2)) as p, daily sero-conversion as p, daily sero-reversion as p, then we have the following equation: p[T] = p[T-1] + p [in the last 24 hours] -p [in the last 24 hours] This can be written as p(T) = ∑ p 0 − ∑ p − T 0 (1) Denote f(s) as the deca…”
BackgroundMethodInfluentialStrategies to Mitigate COVID-19 Resurgence Assuming Immunity Waning: A Study for Karnataka, IndiaPreprint
Adiga, A., Athreya, S., Lewis, B. L., MARATHE, M. V., Rathod, N., Sundaresan, R., Swarup, S., Venkatramanan, S., & Yasodharan, S. (2021) · medRxiv · doi:10.1101/2021.05.26.21257836 · Cited by 8
“As the recent studies using the Manaus, Brazil outbreak show [9,39], disentangling these factors may be complex without additional data.”
ResultHofman, P. M., Bordone, O., Chamorey, E., Benzaquen, J., Schiappa, R., Lespinet‐Fabre, V., Lantéri, E., Brest, P., Mograbi, B., Maniel, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.730577 · Cited by 7
“1) was first detected on the 6th of January 2021 in a traveler returning in Japan coming from Rio de Janeiro (Brazil), found in many individuals in Brazil in the following days, and then rapidly disseminated in many countries (10, 25) (https://virological.”
BackgroundSizyakinа, L. P., Ивановна, А. И., Харитонова, М. В., Zaitseva, N. S., Lyubimov, D. S., Zakurskayа, V. Y., & Тотолян, А. А. (2022) · Medical Immunology (Russia) · doi:10.15789/1563-0625-mof-2490 · Cited by 9
The past, present and future of genomics and bioinformatics: A survey of Brazilian scientists
Rocha, M., Massarani, L., SOUZA, S. J. D., & de Vasconcelos, A. T. R. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2021-0354 · Cited by 6
Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview
Hadizadeh, N., Naderi, M., Khezri, J., Yazdani, M., Shamsara, M., & Hashemi, E. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01002-6 · Cited by 8
Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera
Kannenberg, J., Schnurra, C., Reiners, N., Henschler, R., Buhmann, R., Kaiser, T., Biemann, R., Hönemann, M., Ackermann, G., Trawinski, H., et al. (2021) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2021.100038 · Cited by 6
COVID ‐19 by numbers ‐ infections, cases and deaths
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15377 · Cited by 7
Vidales, E. P. R., Garza‐Carrillo, D., Perez‐Trujillo, J. J., Robles‐Rodríguez, O. A., Salinas-Martínez, A. M., Montes‐de‐Oca‐Luna, R., Treviño‐Garza, C., & de la O-Cavazos, M. E. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27131 · Cited by 7
Tess, B. H., Granato, C., Alves, M. C. G. P., Pintão, M. C. T., Nunes, M. C., Rizzatti, E. G., & Reinach, F. D. C. (2021) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2021.101604 · Cited by 9
Sulcebe, G., Ylli, A., Cenko, F., & Kurti-Prifti, M. (2021) · medRxiv · doi:10.1101/2021.02.18.21251776 · Cited by 6
“%) have been reported in April 2020 in Guilan, Iran and in July 2020 both in Bergamo, Italy and in Manaus, Brazil (32, 33, 34).”
BackgroundTakahashi, S., Peluso, M. J., Hakim, J. M. C., Turcios, K., Janson, O., Routledge, I., Busch, M. P., Hoh, R., Tai, V., Kelly, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.09.09.21263139 · Cited by 6
“Reference (52) (Figure 1) (24) (Figure 4); (25,26) (27,39) (28,29) (30) .”
Self-citationWhy did COVID-19 affect some cities more than others? Insights from Brazil before vaccination
Chauvin, J. P. (2024) · Regional Science Policy & Practice · doi:10.1016/j.rspp.2024.100138 · Cited by 6
Darling, H. S., Parikh, P. M., Vaishnav, R., Verma, A., Gulia, A., Kapoor, A., & Singh, R. K. (2021) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_14_2021 · Cited by 5
Buss, L., & Sabino, É. C. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00396-x · Cited by 4
Self-citationHigh Prevalence of SARS-CoV-2 in an Indigenous Community of the Colombian Amazon Region
Coll, H. A. S., Miller, H., der hamen, C. R.-V., Gastelbondo, B., Novoa, W., Oviedo, M., Rivero, R., Garay, E., & Mattar, S., V (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6040191 · Cited by 5
Goh, F. T., Chew, Y. Z., Tam, C. C., Yung, C. F., & Clapham, H. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100581 · Cited by 5
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
Wei, X., Rong, N., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993754 · Cited by 6
Berry, N. J., Ferguson, D., Kempster, S. L., Hall, J., Ham, C., Jenkins, A., Rannow, V., Giles, E., Leahy, R., Goulding, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23339-x · Cited by 4
Badin, R. C., de Amorim, R. L. O., Aguila, A., & Manaças, L. R. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280891 · Cited by 5
Naveca, F. G., do Nascimento, V. A., Nascimento, F., Ogrzewalska, M., Pauvolid‐Corrêa, A., de Araújo, M. F., Arantes, I., Batista, É. L. R., Magalhães, A. L. Á., Vinhal, F. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33443-1 · Cited by 7
“%) had already been infected with SARS-CoV-2 by October 2020 and speculated a high proportion of reinfection among new cases during the Gamma wave 5,6 .”
Self-citationSARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave
Moyano, L. M., Toledo, A. K., Chirinos, J., Vilchez, P., Cavalcanti, S., Gamboa, R., Ypanaque, J., Meza, M., Noriega, S., Herrera, V., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010794 · Cited by 8
Pan American Health Organization (2023) · Pan American Health Organization eBooks · doi:10.37774/9789275127421 · Cited by 15
Metadata
- Authors
- Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
- Affiliations
- Universidade de São Paulo (BR)
- Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
- Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
- Harvard University (US)
- Imperial College London (GB)
- Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
- Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
- Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
- University of California, San Francisco (US)
- Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
- University of Oxford (GB)
- Institute of Applied Economic Research (BR)
- Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Corresponding author
- Buss, Lewis F.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- Faria, Nuno R.
- ORCID
- Buss, Lewis F.
- Prete, Carlos A.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- de Almeida-Neto, Cesar
- França, Rafael F. O.
- Belotti, Maria C.
- Carvalho, Maria P. S. S.
- Costa, Allyson G.
- Crispim, Myuki A. E.
- Ferreira, Suzete C.
- Fraiji, Nelson A.
- Gurzenda, Susie
- Whittaker, Charles
- Kamaura, Leonardo T.
- Takecian, Pedro L.
- da Silva Peixoto, Pedro
- Oikawa, Marcio K.
- Nishiya, Anna S.
- Rocha, Vanderson
- Salles, Nanci A.
- de Souza Santos, Andreza Aruska
- da Silva, Martirene A.
- Custer, Brian
- Parag, Kris V.
- Barral-Netto, Manoel
- Kraemer, Moritz U. G.
- Pereira, Rafael H. M.
- Pybus, Oliver G.
- Busch, Michael P.
- Castro, Márcia C.
- Dye, Christopher
- Nascimento, Vítor H.
- Faria, Nuno R.
- Sabino, Ester C.
- Venue
- Science
- Published
- 2021-01-15
- Volume
- 371
- Issue
- 6526
- Pages
- 288-292
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7857406
- OpenAlex
- W3112547455
- Cited by
- 488
- References
- 47
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/S0195/1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
- Itau Unibanco Todos pela Saude
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.